Summary
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
Allogene Therapeutics Q1 Earnings Call Highlights
Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April financing.
Allogene Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 60 | $82 | $109.8 | $27.8 | 33.9% |
| RS Ramu Singh CALTON & ASSOCIATES Inc. | 11,170 | $27,254.8 | $20,441.1 | -$6,813.7 | -25% |
| BG Bart Gancher Intech Investment Management LLC | 43,061 | $61,542.28 | $77,940.41 | $16,398.13 | 26.65% |
 Point72 Asset Management LP Point72 Asset Management LP | 221,335 | $429,055.59 | $402,829.7 | -$26,225.89 | -6.11% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 722,928 | $1.42M | $1.32M | -$101,209.92 | -7.14% |
Allogene Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JA Jack Allen Baird | 475,047.43 | $988,098.65 | $902,590.11 | -$85,508.54 | -8.65% |
| RS Roger Song Jefferies | 7,246.38 | $15,579.71 | $13,768.12 | -$1,811.59 | -11.63% |
Allogene Therapeutics Inc. (ALLO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Allogene Therapeutics Inc. ever had a stock split?
Allogene Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | David D. Chang CEO | NASDAQ (NGS) Exchange | 019770106 CUSIP |
| US Country | 152 Employees | - Last Dividend | - Last Split | 11 Oct 2018 IPO Date |
Overview
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. Founded in 2017, Allogene is pioneering in the field of allogeneic chimeric antigen receptor (CAR) T cell therapies with a comprehensive portfolio aimed at addressing various types of cancer. With its headquarters in South San Francisco, California, the company is at the forefront of leveraging cutting-edge genetic engineering technologies to improve cancer treatment outcomes. Allogene Therapeutics has established several strategic alliances with industry and academic partners, including Pfizer Inc., Servier, Cellectis S.A., Notch Therapeutics Inc., The University of Texas MD Anderson Cancer Center, and Foresight Diagnostics, to enhance its research, development, and commercialization efforts across its pipeline of cancer therapies.
Products and Services
- UCART19: A pioneering allogeneic CAR T cell therapy designed for the treatment of relapsed or refractory (R/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL) in both pediatric and adult patients. UCART19 represents a significant advancement by eliminating the need for patient-specific cell therapy products.
- Cemacabtagene Ansegedleucel: Engineered allogeneic CAR T cell therapy targeting CD19, developed for the treatment of large B-cell lymphoma. Currently, it is undergoing a Phase 1b clinical trial for chronic lymphocytic leukemia, showcasing its versatility in targeting B-cell malignancies.
- ALLO-715: An investigational allogeneic CAR T cell therapy in Phase 1 clinical trials for the treatment of R/R multiple myeloma. ALLO-715 demonstrates Allogene's commitment to expanding the potential of CAR T cell therapies beyond B-cell malignancies.
- ALLO-605: Another product candidate for multiple myeloma, ALLO-605 is in a Phase I clinical trial, embodying the company’s initiative in advancing the CAR T cell therapy landscape for this plasma cell cancer.
- ALLO-647: An anti-CD52 monoclonal antibody, expanding the cohort of monoclonal antibodies in Allogene's portfolio and diversifying its approach to immuno-oncology.
- CD70, ALLO-316, and ALLO-329: These candidates target renal cell cancer, advanced or metastatic RCC, and certain autoimmune diseases respectively. Each is in early stages of development, demonstrating Allogene's strategic breadth in targeting a range of cancers and immune-related conditions.
- DLL3: Focused on the treatment of small cell lung cancer and other aggressive neuroendocrine tumors, this product candidate emphasizes Allogene's pursuit of solutions for highly aggressive and hard-to-treat cancers.
- Claudin 18.2: Targeted therapy for gastric and pancreatic cancer, showcasing Allogene's focus on CAR T cell therapies for solid tumors, an area of significant unmet medical need.
